Cover Image
市場調查報告書

生技藥品市場上進步

Advances in the Biologics Market 2014

出版商 Espicom Business Intelligence 商品編碼 316053
出版日期 內容資訊 英文 167 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生技藥品市場上進步 Advances in the Biologics Market 2014
出版日期: 2014年05月01日 內容資訊: 英文 167 Pages
簡介

全球生技藥品市值推算約1,750億美元。市場以治療慢性疾病及往往威脅生命的疾病的高價值產品為特徵,預計以比醫藥品整體市場快的速度繼續成長。

本報告提供生技藥品市場相關調查、市場概要、開發平台分析、各產品分析,及主要製造商的簡介等。

序文

摘要整理

生技藥品市場上進步

  • 市場概要
    • 銷售額分析
  • 開發平台分析
  • 主要企業
    • Roche
    • Amgen
    • Sanofi
    • AbbVie
    • Johnson & Johnson
    • Eli Lilly

抗體複合體

  • 主要企業
  • 關注企業
  • 已經過核准的ADC(藥物複合體)
  • 臨床開發中的ADC

癌症免疫治療藥

  • 主要企業
  • 已經過核准的癌症免疫治療藥
  • 臨床開發中的癌症免疫治療藥

融合蛋白品質

  • 臨床開發中的融合蛋白品質及Fc-最佳化mAb

干擾素(interferon)

  • 肝炎治療IFN
  • 多發性硬化症IFN

白細胞介素抑制劑

  • 已上市IL抑制劑
  • 臨床開發中的IL抑制劑

單株抗體

  • 紮根的主要產品
  • 生技仿製藥mAb的開發
  • 最近認證的治療藥、有潛力治療藥物

肽/pepuchibodi

  • 類升糖素肽受體激動劑
  • Ang1/Ang2抑制劑

附錄:生物製藥管道

來源

圖表清單

目錄

The global biologics market is estimated to be worth around US$175 billion. The market is characterised by high-value products that treat chronic and often life-threatening diseases, and is expected to continue to grow faster than the overall pharmaceutical market.

Table of Contents

Foreword

Executive Summary

Advances in the Biologics Market

  • Market Overview
    • Sales Analysis
      • Key Biologic Products
  • Pipeline Analysis
  • The Key Players
    • Roche
    • Amgen
    • Sanofi
    • AbbVie
    • Johnson & Johnson
    • Eli Lilly

Antibody-Drug Conjugates

  • The Key Players
    • ImmunoGen
    • Seattle Genetics
    • Genentech (Roche)
    • Takeda
  • Companies to Watch
    • Mersana Therapeutics
    • Sorrento Therapeutics
  • Approved ADCs
    • Kadcyla (trastuzumab emtansine)
      • Sales forecast
    • Adcetris (brentuximab vedotin)
      • Sales forecast
  • ADCs in Clinical Development
    • Inotuzumab ozogamicin
      • Sales forecast
      • Clinical trials
    • Glembatumumab vedotin (CDX-011)
      • Clinical trials
    • Teprotumumab
      • Clinical trials
    • RG7593 (DCDT2980S)
      • Clinical trials
    • RG7596 (DCDS4501A)
      • Clinical trials
    • PSMA ADC
      • Clinical trials

Cancer Immunotherapy

  • The Key Players
    • Bristol-Myers Squibb
    • Merck & Co
    • Novartis
    • Roche
  • Companies to Watch
    • Medigene
    • NewLink Genetics
  • Approved Cancer Immunotherapies
    • Yervoy (ipilimumab)
      • Sales forecast
    • Provenge (sipuleucel-T)
      • Sales forecast
  • Cancer Immunotherapies in Clinical Development
    • Dasiprotimut-T Biovest (BiovaxID)
    • Talimogene laherparepvec
      • Sales forecast
      • Clinical trials
    • Pembrolizumab (MK-3475)
      • Agreement With Incyte
      • Amgen Collaboration
      • Partnership With Pfizer
    • Nivolumab
      • Clinical trials
    • RG7446 (MPDL3280A)
      • Clinical trials
    • Tecemotide (L-BLP25)
      • Clinical trials
    • MAGE-A3 ASCI
      • MAGRIT trial results
    • Rindopepimut (CDX-110)
    • AGS-003
    • DCVax-L
    • MVax
    • Algenpantucel-L
      • Clinical trials
    • Bavituximab
      • Clinical trials
    • CTL019
      • Clinical trials

Fusion Proteins

  • Enbrel (etanercept)
    • Sales and forecast
  • Biosimilar Etanercept Development
  • Orencia (abatacept)
    • Sales and forecast
  • Eylea (aflibercept)
    • Sales and forecast
    • Clinical trials
    • Potential combination therapy
  • Alprolix (coagulation factor IX [recombinant], Fc fusion protein)
    • Clinical trials
  • Fusion Proteins and Fc-optimised mAbs in Clinical Development
    • Eloctate (efraloctocog alfa)
      • Clinical trials
    • Atacicept

Interferons

  • IFN for Hepatitis Treatment
    • Current Market Leaders
    • Novel Investigational IFN
      • Peginterferon lambda-1a
        • Clinical trials
  • IFN for Multiple Sclerosis
    • Current Market Leaders
    • IFN in Development for MS
      • Plegridy (peginterferon beta-1a)
        • Sales forecast
        • Clinical trials
      • Relonsiv (interferon beta-1b)

Interleukin Inhibitors

  • Marketed IL Inhibitors
    • Ilaris (canakinumab)
      • Sales and forecast
    • Actemra/RoActemra (tocilizumab)
      • Sales and forecast
    • Stelara (ustekinumab)
      • Sales and forecast
  • IL Inhibitors in Clinical Development
    • Anti-IL-2
      • Daclizumab (DAC HYP)
        • Sales forecast
        • Clinical trials
    • Anti-IL-5
      • Mepolizumab
        • Sales forecast
        • Clinical trials
      • Benralizumab (MEDI-563)
        • Clinical trials
    • Anti-IL-6
      • Sarilumab (REGN88, SAR153191)
        • Clinical trials
      • Sirukumab (CNTO 136)
        • Clinical trials
    • Anti-IL-13
      • Lebrikizumab
        • Clinical trials
    • Anti-IL-17
      • Brodalumab (MEDI6365; AMG-827; KHK4827)
        • Sales forecast
        • Clinical trials
      • Ixekizumab (LY2439821)
        • Sales forecast
        • Clinical trials
      • Secukinumab (AIN457)
        • Clinical trials
    • Anti-IL-23
      • Guselkumab (CNTO 1959)
        • Clinical trials
      • Tildrakizumab
        • Clinical trials

Monoclonal Antibodies

  • Established Key Products
    • Humira (adalimumab)
      • Sales and forecast
    • Avastin (bevacizumab)
      • Sales and forecast
    • Erbitux (cetuximab)
      • Sales and forecast
    • Remicade (infliximab)
      • Sales and forecast
    • Lucentis (ranibizumab)
      • Sales and forecast
    • MabThera/Rituxan (rituximab)
      • Sales and forecast
    • Herceptin (trastuzumab)
      • Sales and forecast
    • Biosimilar mAb Development
      • Adalimumab
      • Bevacizumab
      • Cetuximab
      • Infliximab
      • Rituximab
      • Trastuzumab
  • Recent Approvals and Potential Therapies
    • CD20 Antibodies
    • Gazyva (obinutuzumab)
      • Sales forecast
      • Clinical trials
    • Ocrelizumab (RG1594)
      • Sales forecast
      • Clinical trials
    • EGFr Antibodies
      • Necitumumab (LY3012211)
        • Sales forecast
        • Clinical trials
    • HER2 Antibodies
      • Perjeta (pertuzumab)
        • Sales and forecast
    • VEGF Antibodies
      • Cyramza (ramucirumab)
        • Sales forecast
        • Clinical trials
  • PCSK9 Antibodies
    • Alirocumab (SAR236553, REGN727)
      • Sales forecast
      • Clinical trials
    • Evolocumab (AMG 145)
      • Sales forecast
      • Clinical trials
    • Bococizumab (RN316, PF-04950615)
      • Clinical trials
  • BiTE Antibodies
    • Blinatumomab (AMG 103)
      • Sales forecast
      • Clinical trials
  • CD22 Antibodies
    • Epratuzumab
      • Sales forecast
      • Clinical trials
    • Moxetumomab pasudotox (CAT8015)
      • Clinical trials
  • CD38 Antibodies
    • Daratumumab (JNJ-54767414)
      • Clinical trials
  • Amyloid Beta Antibodies
    • Solanezumab (LY2062430)
      • Sales forecast
      • Clinical trials
    • Gantenerumab (RG1450)
      • Clinical trials
  • Antibodies Targeting the Met Pathway
    • Onartuzumab (RG3638)
      • Clinical trials
    • Rilotumumab (AMG 102)
      • Sales forecast
      • Clinical trials

Peptides/Peptibody

  • Glucagon-like Peptide Agonists
    • Eperzan/Tanzeum (albiglutide)
      • Sales forecast
      • Clinical trials
    • Dulaglutide (LY2189265)
      • Sales forecast
      • Clinical trials
  • Ang1/Ang2 Inhibitor
    • Trebananib (AMG 386)
      • Sales forecast
      • Clinical trials

Appendix: Biologics Pipeline

Sources

Back to Top